270 related articles for article (PubMed ID: 37207347)
1. Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy.
Mao L; Ma P; Luo X; Cheng H; Wang Z; Ye E; Loh XJ; Wu YL; Li Z
ACS Nano; 2023 Jun; 17(11):9826-9849. PubMed ID: 37207347
[TBL] [Abstract][Full Text] [Related]
2. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
3. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
4. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
5. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
6. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
Yin Q; Wang Y; Xiang Y; Xu F
Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
[TBL] [Abstract][Full Text] [Related]
9. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
10. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
11. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy.
Zhang Y; Chen J; Shi L; Ma F
Mater Horiz; 2023 Feb; 10(2):361-392. PubMed ID: 36541078
[TBL] [Abstract][Full Text] [Related]
12. Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review.
Zhao J; Du G; Sun X
J Biomed Nanotechnol; 2021 Nov; 17(11):2099-2113. PubMed ID: 34906272
[TBL] [Abstract][Full Text] [Related]
13. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
14. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
[TBL] [Abstract][Full Text] [Related]
15. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
16. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
17. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
18. Nanovaccines: A game changing approach in the fight against infectious diseases.
Priyanka ; Abusalah MAH; Chopra H; Sharma A; Mustafa SA; Choudhary OP; Sharma M; Dhawan M; Khosla R; Loshali A; Sundriyal A; Saini J
Biomed Pharmacother; 2023 Nov; 167():115597. PubMed ID: 37783148
[TBL] [Abstract][Full Text] [Related]
19. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
Xu F; Yuan Y; Wang Y; Yin Q
Biomed Pharmacother; 2023 Feb; 158():114117. PubMed ID: 36528914
[TBL] [Abstract][Full Text] [Related]
20. Nanovaccines for cancer immunotherapy.
Zhang Y; Lin S; Wang XY; Zhu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
